Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. A numerical improvement in O.

Gilead Provides Update on Phase 3 EVOKE-01 Study

Eli Lilly

Vertex Pharmaceuticals

For the past two years, biotech stocks have faced unfavorable conditions. These stocks have been on a downward spiral after reaching their pick at the beginning of 2021.

Bio-Revolution: 3 Biotech Stocks With Breakthrough Potential

AstraZeneca

Merck

By Feb. 1, the federal government will send an initial offer for each of the 10 drugs selected for the first round of negotiations under the program, which was established under the Inflation Reduction Act and touted by President Joe Biden as part of a broader effort to drive down healthcare costs. Yet several lawsuits challenging the program could also reach turning points in the coming months, raising the prospect that some elements of the program could be stalled before they get off the ground.

Medicare drug price negotiations hit critical phase

Amgen

Centene

Cencora Inc

Catalent

Medtronic

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.

Stocks This Week: Buy The Biotech Stocks: Amgen And Gilead

Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.

Top Stock Picks for 2024: Gilead Sciences

Biotechnology company Gilead Sciences (NASDAQ: GILD ) wasn't a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024.

Gilead's Quiet Revolution: Is GILD the Next Big Stock to Soar?

Agilent Technologies

Bristol-Myers

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Estee Lauder

Emerson Electric

Etsy

Huntington Ingalls Industries

Harley-Davidson

Honeywell

International Flavors & Fragrances

Kenvue

McDonald's

Altria

NIKE

Otis Worldwide

PepsiCo

Pfizer

Polaris

Ross Stores

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map

Entergy

International Paper

This article introduces a dividend stock selection process called YARP (Yield At a Reasonable Price) that prioritizes risk management and total return. YARP aims to identify stocks with historically high dividend yields that are currently undervalued and have the potential for price appreciation. Within this article, I provide three stocks that meet the YARP criteria: Entergy, International Paper, and Gilead Sciences, highlighting their solid fundamentals, profitability, and dividend situations.

My Top 3 YARP Stocks Right Now (Yield At A Reasonable Price)

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since the ball dropped in Times Square.

3 health care stocks off to strong starts in 2024

Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Novartis

Sanofi

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences is recovering from reduced Veklury (remdesivir) revenue following the height of the COVID-19 pandemic. The company, however, is making progress in HIV product sales and oncology, the latter it expects to make up one-third of its business by 2030. Gilead's strong free cash flow generation easily covers its dividend payment, and we find its ~3.6% dividend yield quite attractive. Gilead's dividend growth potential is phenomenal, in our view.

Gilead's Dividend Growth Potential Looks Phenomenal

Axcelis Technologies

Cisco Systems

Expedia

Fortinet

Intel

Netflix

The Nasdaq 100 had a banner year. After a disastrous 2022 that saw the tech-laden index lose one-third of its value, it rebounded sharply in 2023 soaring 55% to hit a new all-time high.

Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cel.

U.S. FDA Approves Label Update for Kite's Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech.

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone'

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

Compugen

Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugen's pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, which is targeting cancer.   Per the agreement, Compugen will be responsible for the ongoing pre-clinical development and future Phase 1 study of COM503 after which Gilead will have the sole right to develop and commercialize the drug.

Gilead Sciences and Compugen strike commercialization deal for immunotherapy program

Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage development and commercialization of Anti-IL 18 binding protein antibodies with potential to treat various types of tumors.

Compugen stock rockets on anti-tumor drug deal with Gilead

FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.

Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

Gilead Sciences, Inc. had strong quarterly results, with total product sales of $6.3 billion and strong growth in HIV and Oncology. The company has several milestones, including the success of Trodelvy with over $1 billion in annualized sales. Gilead Sciences is accelerating its cancer business, with over $3 billion in annualized sales and a goal to contribute 1/3 of revenue by 2030.

Gilead Sciences Is Building A Diversified Portfolio

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced data from follow-up analyses of three studies of Yescarta® (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory (R/R) non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. This included ZUMA-1 (Abstract #4864) showing that patients with refra.

Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the results of four new analyses supporting the use of Tecartus® (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). These results include four-year overall survival (OS) data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR T.

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite's Tecartus® in Patients With Aggressive Blood Cancers

News for Gilead Sciences Stock (GILD)